Sign up to save your podcastsEmail addressPasswordRegisterOrContinue with GoogleAlready have an account? Log in here.
December 31, 2019NOTCH1: The Clinical and Basic Science Behind it - Silvia Deaglio, MD, PhDFirst- and Second-Line Treatment Updates in CLL: The Role of Targeted Therapy14 minPlay
December 31, 2019Treatment for BTKi Progressors - Richard R. Furman, MDFirst- and Second-Line Treatment Updates in CLL: The Role of Targeted Therapy21 minPlay
December 31, 2019Richter's: Who will Get, What to Do? - Jennifer R. Brown, MD, PhDFirst- and Second-Line Treatment Updates in CLL: The Role of Targeted Therapy20 minPlay
December 31, 2019Panel Discussion: Next Line Treatment in CLL - Richard R. Furman, MD; Matthew S. Davids, MD; Thomas J. Kipps, MD; Jennifer R. Brown, MD, PhDFirst- and Second-Line Treatment Updates in CLL: The Role of Targeted Therapy11 minPlay
December 31, 2019Immune Function in CLL: What is Wrong and Why? - Neil E. Kay, MDFirst- and Second-Line Treatment Updates in CLL: The Role of Targeted Therapy31 minPlay
December 31, 2019CLL Case Discussions - Richard R. Furman, MD; Jennifer R. Brown, MD, PhD; Matt S. Davids, MD, MMSc; Neil E. Kay, MD; Kanti R. Rai, MDFirst- and Second-Line Treatment Updates in CLL: The Role of Targeted Therapy49 minPlay
December 31, 2019Chemotherapy vs Novel Agents in Young CLL Patients: Is There Still a Role for Chemotherapy? - Neil E. Kay, MDPositioning PI3K Inhibitors in the CLL/SLL Treatment Paradigm: New Options for Relapsed/Refractory Disease17 minPlay
December 31, 2019Novel Agents in Elderly CLL Patients: Should the Approach be Different? - Jennifer A Woyach, MDPositioning PI3K Inhibitors in the CLL/SLL Treatment Paradigm: New Options for Relapsed/Refractory Disease21 minPlay
December 31, 2019Combination of Novel Agents: Is this the Final Answer? - John N. Allan, MDPositioning PI3K Inhibitors in the CLL/SLL Treatment Paradigm: New Options for Relapsed/Refractory Disease25 minPlay
December 31, 2019Panel Discussion: Front-line CLL Treatment - Richard R. Furman, MD; Neil E. Kay, MD; Jennifer A. Woyach, MD; John N. Allan, MDPositioning PI3K Inhibitors in the CLL/SLL Treatment Paradigm: New Options for Relapsed/Refractory Disease5 minPlay